Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals Shares Homepage, Bse Sensex,NSE Nifty,Latest Prices,Live News,Gainers Losersd,Top Performer,Market Commentry,Live Quotes,Bulk Deals
myirislogo
22 November, 2024 11:10 IST
Earnings
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Yes Bank 24.08 42.49
Tata Stl 136.10 30.24
Ong Corp 255.50 95.26
I T C Lt 439.00 28.72
Ntpc Ltd 318.20 88.67
Clear All Clear Last
Equity
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
Market Pulse
Leaders
Laggards
FII Activity
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Quotes
Charts
Financials
Recent News
Broker Research
Research
Research Reports
Medicamen Biotech Limited
Pharmaceuticals - Formulations
BSE:531146NSE:MEDICAMEQBloomberg:MDCB@INReuters:MEBI.BO
Market Lot: 1Face Value: 10ISIN Demat: INE646B01010
QuotesChartsFinancialsResearchRecent News
MF HoldingBSE/NSE Notices
Company Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12-JAN-24
Closure of Trading Window 30-DEC-23
Announcement under Regulation 30 (LODR)-Newspaper Publication 11-NOV-23
Un-Audited Financial Results- Quarter And Half Year Ended September 30, 2023 10-NOV-23
Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Half Year Ended On September 30, 2023 02-NOV-23
Announcement Under Regulation 30 Of LODR - Clarification On Price Movements 31-OCT-23
Clarification sought from Medicamen Biotech Ltd 31-OCT-23
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 19-OCT-23
Closure of Trading Window 03-OCT-23
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 28-SEP-23
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 28-SEP-23
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 28-SEP-23

© All rights reserved. IRIS Business Services Limited
Disclaimer